Read More

Sanofi Makes Statement On FTC Challenge To Proposed License Agreement With Maze Therapeutics; Says We Respectfully Disagree With The Action By The FTC Which Also Delays Potential Advancements That Could Impact The Lives Of Patients

Sanofi is disappointed with the Federal Trade Commission's announcement that it is seeking a preliminary injunction against a proposed licensing agreement between Sanofi and Maze Therapeutics. The agreement, announced on

SNY

Read More

MaxCyte Announces CEO Transition; Doug Doerfler, President And CEO, To Retire, Maher Masoud To Succeed, Effective Jan 1, 2024; Reiterating 2023 Core Revenue Guidance Of $28M-$30M Vs $35M Est. Expects To Exceed Prior SPL Program-Related Guidance Of $10M

Doug Doerfler, President and CEO, to Retire Effective December 31, 2023; will continue to serve as an advisor to MaxCyte Maher Masoud, EVP, Head of Global Business Development and Chief Counsel, to Succeed Mr.

MXCT

Read More

L3Harris Continues Board Refreshment And Provides Update On Shareholder Value Creation Activities; Kirk Hachigian And Bill Swanson Appointed To Board Of Directors; Board Forms Business Review Committee With William Brown As Special Advisor

Kirk Hachigian and Bill Swanson Appointed to Board of DirectorsBoard Forms Business Review Committee with William Brown as Special AdvisorL3Harris Technologies ("L3Harris") (NYSE:LHX) today announced that its Board of

LHX